menu
    • menu

    Company profile for BioMarin Pharmaceutical

    NEW Drugs in Dev: 26
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    With seven products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs. At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission�...
    With seven products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs. At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioMarin PharmaceuticalUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    770 Lindaro Street San Rafael, CA 94901
    Telephone
    Telephone
    415-506-6700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biomarin.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biomarin/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioMarin Bounces Back as Voxzogo Beats Expectations
    BioMarin Bounces Back as Voxzogo Beats Expectations

    21 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/biomarin-bounces-back-as-voxzogo-performs-bigger-than-expected-in-new-indication

    BIOSPACE
    21 May 2026
    Share Share
    BioMarin's Drug Show Significant Growth Gains in Children
    BioMarin's Drug Show Significant Growth Gains in Children

    20 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biomarins-drug-shows-significant-growth-gains-children-late-stage-trial-2026-05-20/

    REUTERS
    20 May 2026
    Share Share
    BioLineRx and Hemispherian: GLIX1 Shows Anti-Tumor Effect in GBM
    BioLineRx and Hemispherian: GLIX1 Shows Anti-Tumor Effect in GBM

    19 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/biomarin-suffers-another-blow-to-rare-disease-portfolio-in-phase-3-flop

    BIOSPACE
    19 May 2026
    Share Share
    BioMarin Updates Phase 3 Trial of BMN 401 in Children with ENPP1
    BioMarin Updates Phase 3 Trial of BMN 401 in Children with ENPP1

    18 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biomarin-provides-update-on-phase-3-trial-for-bmn-401-in-children-aged-1-12-with-enpp1-deficiency-302774207.html

    PR NEWSWIRE
    18 May 2026
    Share Share
    BioMarin Genetic Disease Therapy Shows Mixed Phase 3 Results
    BioMarin Genetic Disease Therapy Shows Mixed Phase 3 Results

    18 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biomarins-genetic-disease-therapy-shows-mixed-results-late-stage-study-2026-05-18/

    REUTERS
    18 May 2026
    Share Share
    Biomarin Unveils Q1 2026 Financial And Operating Results
    Biomarin Unveils Q1 2026 Financial And Operating Results

    05 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biomarin-reports-first-quarter-2026-financial-and-operating-results-302760669.html

    PR NEWSWIRE
    05 May 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search